TRANSLATIONAL RESEARCH IN ONCOLOGY (TRIO), a global academic clinical research organization, recently announced the appointment of two new members to the Company’s Board of Directors. Joining the board are Peter Fasching, MD, and Hari Kumar, PhD. Together, they bring decades of leadership in key areas, including product and clinical development leadership.
About Dr. Fasching
Peter Fasching, MD
DR. FASCHING currently serves as Associate Professor of Gynecology and Obstetrics Translational Medicine at the University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Germany. He obtained his MD at the University of Cologne, Medical School, and in 2006 he earned his Board Certification in Gynecology and Obstetrics at University Hospital Erlangen. He was a research fellow in the Department of Hematology/Oncology, University of California, Los Angeles.
Since 2011, Peter has served as Head of the Clinical Trial Unit and Coordinator of the Breast Cancer Center and Gynecologic Oncology Center at the University Hospital Erlangen. Dr. Fasching has also served as a member of the Steering Committee and Principal Investigator in several key breast cancer trials.
About Dr. Kumar
Hari Kumar, PhD
DR. KUMAR is a pharmaceutical executive with more than 25 years of experience in the industry. He trained as an immunologist at University College London, where he completed his PhD, followed by a postdoctoral fellowship at Tufts New England Medical Center in Boston, and another fellowship at the Marie Curie Cancer Research Centre in the United Kingdom.
Dr. Kumar started his pharmaceutical career at Roche, first in basic research, subsequently moving to sales and marketing, lifecycle management, and finally to business development. He was also involved in guiding cross-functional teams for the transplantation franchise in Roche. In his role as Lead In-Licensing Person, he was instrumental in partnerships with Isotechnika, Biotie, Biocryst, and Actelion.
Dr. Kumar went to Amira in 2007, where he led the process that resulted in the acquisition by Bristol-Myers Squibb in 2011. His second major acquisition came as Chief Executive Officer and Board member of Adheron Therapeutics, Inc, which was bought by Roche.
